Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials.
AUTOR(ES)
Amor, B
RESUMO
Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p less than 0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1002191Documentos Relacionados
- Feverfew in rheumatoid arthritis: a double blind, placebo controlled study.
- Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients.
- Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.
- Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis.
- Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study.
